Inogen Inc
Close on Oct 19, 2026
- Market cap
- $177.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $95.10M | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $85.10M | $-0.30 | $-0.14 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | During market hours | $81.70M | $-0.26 | $-0.15 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $92.40M | $-0.20 | $-0.02 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $92.30M | $-0.15 | $-0.02 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | $82.30M | $-0.25 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | During market hours | $80.10M | $-0.41 | $-0.24 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $88.80M | $-0.25 | $-0.11 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted EBITDAnon-GAAP | full year 2026 | $4.00M | New |
| reported revenue | full year 2026 | $355.00M to $361.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Inogen filed with the SEC
INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inogen Announces Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces $30 Million Share Repurchase Program
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration with Yuwell
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Results of operations · EX-99.1 to Form 8-K
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inogen Announces Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Names Michael Bourque As New Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Leadership Change with the
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Completes Acquisition of Physio-Assist
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
INOGEN ANNOUNCES CFO TRANSITION PLAN
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Inogen Announces Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Third Quarter 2022 Financial Results
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
Inogen Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Board of Director Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Names Kristin Caltrider as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inogen Announces Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inogen Announces Preliminary, Unaudited Full Year and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K